Lead Product(s) : Mirivadelgat
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Foresee Doses First Patient in Phase 2 WINDWARD Study for PH-ILD
Details : FP-045 (mirivadelgat) is an oral aldehyde dehydrogenase 2 activator, It is being evaluated for the treatment of pulmonary hypertension-associated interstitial lung disease.
Product Name : FP-045
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 15, 2025
Lead Product(s) : Mirivadelgat
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable